[
    [
        {
            "time": "2021-10-22",
            "original_text": "Novartis Mulls Selling Underperforming Unit As Sales Decline Continues",
            "features": {
                "keywords": [
                    "Novartis",
                    "Selling",
                    "Underperforming",
                    "Unit",
                    "Sales",
                    "Decline"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-10-22",
            "original_text": "Novartis (NVS) Q3 2021 Earnings Call Transcript",
            "features": {
                "keywords": [
                    "Novartis",
                    "Q3",
                    "Earnings",
                    "Call",
                    "Transcript"
                ],
                "sentiment_score": 0.0,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 5,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 6,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-10-22",
            "original_text": "Novartis (NVS) Q3 Earnings Beat, Sandoz Under Strategic Review",
            "features": {
                "keywords": [
                    "Novartis",
                    "Q3",
                    "Earnings",
                    "Beat",
                    "Sandoz",
                    "Strategic",
                    "Review"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        },
        {
            "time": "2021-10-22",
            "original_text": "Novartis Boosts Guidance For These Key Drugs After Their Bang-Up Quarter",
            "features": {
                "keywords": [
                    "Novartis",
                    "Boosts",
                    "Guidance",
                    "Key",
                    "Drugs",
                    "Bang-Up",
                    "Quarter"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 7,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 8,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-10-22",
            "original_text": "The Daily Biotech Pulse: Moderna Gains On Vaccine News, Novartis Reports Q3 Beat, Adcom Reviews Authorization Of Pfizer-BioNTech's Vaccine For Children",
            "features": {
                "keywords": [
                    "Biotech",
                    "Moderna",
                    "Vaccine",
                    "Novartis",
                    "Q3",
                    "Beat",
                    "Adcom",
                    "Reviews",
                    "Authorization",
                    "Pfizer-BioNTech",
                    "Children"
                ],
                "sentiment_score": 0.8,
                "policy_related": "true",
                "investment_strategy": "false",
                "sector_focus": [
                    "biotechnology",
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 6,
                "Impact": 5,
                "Duration": 4,
                "Entity_Density": 8,
                "Market_Scope": 8,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-10-22",
            "original_text": "Novartis Starts Review of Generic-Drug Unit",
            "features": {
                "keywords": [
                    "Novartis",
                    "Starts",
                    "Review",
                    "Generic-Drug",
                    "Unit"
                ],
                "sentiment_score": -0.4,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-10-22",
            "original_text": "Novartis mulls spinning off Sandoz generic drug unit",
            "features": {
                "keywords": [
                    "Novartis",
                    "mulls",
                    "spinning",
                    "off",
                    "Sandoz",
                    "generic",
                    "drug",
                    "unit"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-10-22",
            "original_text": "Novartis May Spin Off or Sell Ailing Sandoz Generics Unit",
            "features": {
                "keywords": [
                    "Novartis",
                    "May",
                    "Spin",
                    "Off",
                    "Sell",
                    "Ailing",
                    "Sandoz",
                    "Generics",
                    "Unit"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-10-22",
            "original_text": "Novartis may divest generic unit Sandoz as price pressures mount",
            "features": {
                "keywords": [
                    "Novartis",
                    "divest",
                    "generic",
                    "unit",
                    "Sandoz",
                    "price",
                    "pressures",
                    "mount"
                ],
                "sentiment_score": -0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "Correlation": 9,
                "Sentiment": 3,
                "Importance": 7,
                "Impact": 6,
                "Duration": 4,
                "Entity_Density": 9,
                "Market_Scope": 3,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 7
            }
        },
        {
            "time": "2021-10-22",
            "original_text": "Novartis delivers solid Q3 results, with strong growth in Innovative Medicines. Announces strategic review of Sandoz",
            "features": {
                "keywords": [
                    "Novartis",
                    "solid",
                    "Q3",
                    "results",
                    "strong",
                    "growth",
                    "Innovative",
                    "Medicines",
                    "strategic",
                    "review",
                    "Sandoz"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "pharmaceuticals"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 5,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 8
            }
        }
    ]
]